TrialsgrambetaRCTs are beautiful

SHIFT

2010

Systolic Heart failure treatment with the If inhibitor ivabradine Trial

In 6,558 patients with HFrEF (EF ≤ 35%) in sinus rhythm with heart rate ≥ 70 bpm, ivabradine reduced cardiovascular death or hospitalisation for worsening heart failure compared with placebo.

Result

Efficacy: Composite of cardiovascular death or hospitalisation for worsening heart failureHR 0.82 (95% CI 0.75-0.90) · P < 0.0001

Below 1 favours ivabradine, above 1 favours placebo.

Event rates
Absolute difference
5 points
NNT
20

Absolute difference and NNT are derived from the event rates.

Also reported: Driven mainly by fewer HF hospitalisations.

Original publication
Subtopic
If-channel inhibitor
Design
Double-blind placebo-controlled RCT
Relevance
Supporting: context rather than must-know.
Source
Swedberg K, et al. Lancet. 2010;376(9744):875-885.doi 10.1016/S0140-6736(10)61198-1

Discussion & critique

Benefit confined to sinus rhythm with heart rate ≥70 bpm, and background beta-blocker doses often submaximal. Established ivabradine for HFrEF with elevated heart rate despite maximally tolerated beta-blockade.

Discussed in podcasts